Objective
as above
Background Rationale
See study summary document.
Description of Project
This is an exciting time in T1D research. The first disease modifying therapy in 100 years was licensed in the USA in 2022, hybrid closed loop therapy is becoming commonplace in developed countries and stem cell derived beta cells have been shown to be able to control blood glucose levels. However, T1D still represents a major burden to those affected and their families, and currently less than 30% of individuals achieve op4mal glycaemic control.
Support from DUK and JDRF over the last 8 years and particularly in the last year has allowed the UKT1D-RC to capitalise on recent developments and prepare for the future. Here we show how the work of the UKT1D-RC and its partners spans the whole spectrum of studies contributing to “Moving towards Insulin Free T1D” from discovery science to clinical implementaion, and describe out plans for the next 2 years.
Anticipated Outcome
See study summary document.
Relevance to T1D
See study summary document.